Article Figures & Data
Tables
- TABLE 1
Characteristics associated with all-cause in-hospital mortality among patients with sepsis due to carbapenem-resistant Pseudomonas aeruginosa
Characteristica (n = 215) Survivor (n = 169) Nonsurvivor (n = 46) P value Age, median (yr [IQR]) 58 (44–67) 61 (52–70) 0.060 Age ≥65 yr (n [%]) 59 (34.9) 19 (41.3) 0.424 Yr of infection (n [%]) 0.224 2012 59 (34.9) 17 (37.0) 0.797 2013 42 (24.9) 7 (15.2) 0.167 2014 28 (16.6) 13 (28.3) 0.073 2015 40 (23.7) 9 (19.6) 0.556 ICU admission (n [%]) 86 (50.9) 31 (67.4) 0.046 Length of stay (median days [IQR])b 3 (1–18) 10 (1–29) 0.034 Hospital-acquired infection (n [%])c 93 (55.0) 33 (71.7) 0.041 Time to appropriate treatment (mean ± SD h)d 16.3 ± 27.6 28.5 ± 77.5 0.302 Antibiotic treatment (n [%])e,f 0.089 Aminoglycoside monotherapy 24 (14.2) 15 (32.6) 0.004 Colistin monotherapy 13 (7.7) 1 (2.2) 0.311 Cefepime monotherapy 74 (43.8) 14 (30.4) 0.102 Fluoroquinolone monotherapy 10 (5.9) 4 (8.7) 0.505 Piperacillin-tazobactam monotherapy 38 (22.5) 8 (17.4) 0.455 Aztreonam monotherapy 1 (0.6) 1 (2.2) 0.383 Ceftolozane/tazobactam monotherapy 1 (0.6) 0 (0.0) >0.999 Combination therapy 8 (4.7) 3 (6.5) 0.705 Infection site (n [%]) 0.081 Intraabdominal 9 (5.3) 3 (6.5) 0.754 Respiratory tract 74 (43.8) 30 (65.2) 0.010 Bloodstream/endovascular 17 (10.1) 4 (8.7) >0.999 Urinary tract 43 (25.4) 3 (6.5) 0.004 Skin/soft tissue/osteomyelitis 26 (15.4) 6 (13.0) 0.692 Previous hospitalization (n [%])g 151 (89.3) 46 (100) 0.015 Invasive surgical procedure (n [%])h 86 (50.9) 23 (50.0) 0.915 Central venous catheter (n [%])h 133 (78.7) 32 (69.6) 0.194 Urinary catheter (n [%])h 107 (63.3) 32 (69.6) 0.432 Other invasive device (n [%])h 37 (21.9) 11 (23.9) 0.771 Mechanical ventilation (n [%]) 105 (62.1) 43 (93.5) <0.001 Previous antibiotic exposure (n [%])i 131 (77.5) 42 (91.3) 0.036 Carbapenemi 81 (47.9) 27 (58.7) 0.195 Vasopressor requirement (n [%]) 70 (41.4) 41 (89.1) <0.001 Immunosuppression (n [%]) 56 (33.1) 28 (60.9) 0.001 Solid organ transplantation 14 (8.3) 7 (15.2) 0.160 Stem cell transplantation 18 (10.7) 5 (10.9) >0.999 Acute kidney injury (n [%])j 48 (28.4) 13 (28.3) 0.985 SIRS criteria (median [IQR]) 3 (2–3) 3 (2–3) 0.541 Charlson comorbidity index (median [IQR]) 6 (3–8) 7 (5–11) 0.007 APACHE II score (median [IQR]) 13 (10–17) 15 (12–19) 0.030 ↵a IQR, interquartile range; SD, standard deviation; APACHE II, Acute Physiology and Chronic Health Evaluation II.
↵b Before index culture.
↵c Hospitalized >48 h before index culture without previous evidence of infection.
↵d Treatment with an agent to which the organism was phenotypically susceptible in vitro.
↵e Monotherapy defined as receipt of <2 antibiotics to which the organism was susceptible in vitro as definitive therapy for ≥48 h.
↵f Combination therapy defined as receipt of ≥2 antibiotics to which the organism was susceptible in vitro as definitive therapy for ≥48 h.
↵g Within the preceding 6 months.
↵h During the index hospitalization before index culture.
↵i Within the preceding 3 months.
↵j Determined by diagnosis code as recorded by a treating physician.
- TABLE 2
Multivariable log-binomial regression model of variables associated with all-cause in-hospital mortality among patients with carbapenem-resistant Pseudomonas aeruginosa sepsis
Variable Crude RRa (95% CI) P value Adjusted RRa (95% CI) P value Aminoglycoside monotherapya 1.35 (1.04–1.75) 0.003 1.72 (1.03–2.85) 0.037 Vasopressor requirement 7.68 (3.16–18.69) <0.001 6.85 (2.71–17.35) <0.001 Charlson comorbidity index 1.15 (1.04–1.96) 0.005 1.16 (1.05–1.90) 0.001 APACHE II score 1.07 (1.01–1.13) 0.036 1.01 (0.98–1.04) 0.394 ↵a RR, risk ratio. Comparator: all other monotherapies.
